Europe ::

One of the most regulated and evolved worldwide, the EU market has been a veritable learning ground for Torrent’s exports of generics and dossier licensing.

Central & Eastern Europe: Torrent uses its own brand name and strategic alliances with leading companies to market its products in Romania and Poland.

With Poland as the hub, the Company aims to spread operations in the CEE markets, especially neighboring countries like the Czech Republic, Slovakia, Hungary, etc.

Western Europe: The world’s third largest pharma market, Germany, is the lynchpin of Torrent’s entire Western Europe strategy. Torrent consolidated its presence in Germany with the acquisition of Heumann Pharma Generics, a Pfizer group company, which had sales of Euro 50 million for the fiscal year ended 30th Nov 04 and is ranked 11th in the German generic market.

This acquisition would give Torrent access to the 90-year old “Heumann” brand name, 315 marketing authorizations and 34 product registration applications, together giving TPL a strong presence in Germany. Germany is Euro 8 billion generic pharmaceutical market, EU’s biggest with high generic penetration and expected to grow attractively. Moreover, Heumann’s product portfolio provides a good strategic fit and strong market position to Torrent, with cardiovascular, gastro-intestinal and anti infective therapies constituting around 75 % of the portfolio.

Torrent's strategy for the European market can be summed up as:

• Exploring possibilities of Research and Development collaborations with EU based pharmaceutical companies.

• To look at scope for joint ventures getting a foot hold in the most attractive markets in Europe.

Contact Info ::

Business Opportunities ::

The company has business opportunities for interested companies for the following segments:

Generic Drugs: Torrent provides new and innovative Finished Dosage Forms to its clients at competitive prices and on a fast track. This is made possible by the highly competitive market in India, a 'patent haven'. India being a country with no product patents, there is fierce competition among companies to improve their processes and thus have the best possible technologies and creative brains with them.

Torrent has forged many alliances with companies in Western Europe for marketing of finished formulations. Torrent has a highly qualified Product Development Team. The dossiers comply with the strict EU standards and ICH guidelines. The forms are licensed out, and the companies are invited to enter into supply tie ups with us for the delivery of the finished formulation.

TPL is always on the look out for alliances in Europe to market their products. In order to get more information, please contact the Europe Team.

APIs: Torrent has a well established API (Active Pharmaceutical Ingredient) manufacturing plant, which was recently upgraded to the US FDA standards to satisfy the most stringent GMP guidelines worldwide. Torrent has a vast experience and an interesting product portfolio for the same.

The APIs are not only of internationally accepted quality standards, there is also a wide range available for the customer to choose from. Please contact the Europe Team for more information.

Customized Production: The Torrent Research and Development center is well equipped for development and implementation of new processes. These support R&D facilities coupled with process scale-up and plant-scale productions make Torrent an ideal partner for companies looking towards development of unique formulations.

We offer wide range of NDDS technologies. Among the many dosage forms, Torrent offers sustained release zero dissolution kinetics for reducing dosage frequency as well as delayed release capsules for targeted release in the intestine, as well as bilayered and mouth melting tablets for special patient categories. Our team of specialized scientists can provide our customers with sophisticated processes well adapted to their real needs.

Confidentiality is an important and essential part of our services and ensures total guarantee and discretion for our clients.

Further detailed information can be received from the Research and Development section or the Europe Team of the company.